Bipolar Disorders最新文献

{"title":"Will We Soon See a Low Cost, Small Portable Device for the Therapeutic Monitoring of Lithium? An Implementation Science Investigation","authors":"Santiago Pedraza-Sanabria, Seetal Dodd, Angela Marianne Paredes Castro, Lana J. Williams, Luis Fernando Giraldo-Cadavid, Rosa Helena Bustos","doi":"10.1111/bdi.70009","DOIUrl":"10.1111/bdi.70009","url":null,"abstract":"<p>Lithium is a first-line medication for the treatment of bipolar disorder [<span>1</span>], and is included on the World Health Organization list of essential medicines [<span>2</span>]. Despite this, lithium use is declining in North America and Europe [<span>3</span>]. The need to achieve a narrow therapeutic range means that some clinicians and patients opt for other alternatives. Currently, lithium therapeutic drug monitoring (TDM) is a barrier for new patients, increases patient burden, is stigmatizing, and may contribute to treatment noncompliance. In some rural and remote locations, and outside of major urban centres in developing economies, lithium TDM may not be available and this essential medicine cannot be prescribed. Recent technological advances indicate the potential to develop a small portable device for the TDM of lithium [<span>4</span>]. Our research group is currently developing a portable device for the TDM of lithium and has conducted focus groups to understand where this device is needed and what design of device will best serve that need (Figure 1). This project bridges the gap between technological innovations and the consumer by using an implementation science framework to explore barriers and facilitators to adopting this new technology.</p><p>The Group 1 video (clinicians) was a 37-min recording, and the Group 2 video was 33 min, Group 3 was 54 min, and Group 4 was 50 min. The codes commonly mentioned were concerned with the design of the novel device, including cost, features, and what information the device would display. Codes referencing toxicity, adverse events, and being outside of the therapeutic window were also commonly mentioned.</p><p>A dissenting option was expressed by one of the participants with lived experience, who felt that the current system worked well for her and change was not required. Several participants also mentioned that they would like the device to also measure liver and thyroid function.</p><p>A small portable device for the TDM of lithium is expected to be developed in the near future and several separate research groups may be currently working on this tool. Our study has suggested some key design features that may maximize the usefulness of the device, aid in making lithium available to more patients, and make the lived experience of lithium treatment less of a burden. Firstly, everything possible should be done to minimize the cost of the device. Some participants may suggest an increased range of functions for the device, but any impact on cost for these functions may negate their benefit. For example, it is not necessary that the device should also measure liver and thyroid function, as changes in liver and thyroid health occur slowly and an annual test is sufficient, whereas blood lithium levels can change suddenly. Adding these extra functions may be an unnecessary increase in device costs, and receiving results from other variables may be confusing to patients and create more s","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"27 4","pages":"334-337"},"PeriodicalIF":5.0,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.70009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Type, Impacts, and Experiences of Peer Support for People Living With Bipolar Disorder: A Scoping Review","authors":"Emma Morton,&nbsp;Elsy Willis,&nbsp;Jeff Brozena,&nbsp;Andrew Kcomt,&nbsp;Erin E. Michalak","doi":"10.1111/bdi.70006","DOIUrl":"10.1111/bdi.70006","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Internationally, mental health policy has highlighted the exchange of peer support between people with lived experience as a key component of recovery-oriented care. There is some evidence to support the benefits of peer support in mixed-diagnosis groups, major depressive disorder, and schizophrenia. However, no reviews have specifically described the types and impacts of peer support interventions for bipolar disorder (BD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Analysis</h3>\u0000 \u0000 <p>A scoping review was conducted to explore the type, outcomes, and experience of peer support interventions in BD. Databases searched were MEDLINE, EMBASE, and PsycINFO, using terms related to peer support and BD. Extracted data included study design, participant demographics, intervention characteristics, and qualitative or quantitative data on outcomes and experiences.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty studies met eligibility criteria and were included in the review. A diverse array of interventions incorporating peer support were evaluated, including unstructured face-to-face group programs, peer-facilitated psychoeducation, and web-based psychoeducation with accompanying peer support. Quantitative studies largely assessed clinical outcomes, with some attention to functioning and quality of life. Qualitative data included observations of interaction patterns and subjective experiences of programs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>Given this heterogeneous literature, the effects of peer support in BD cannot be firmly concluded. However, qualitative research and rates of engagement with peer support programs are suggestive of subjective appeal. Priorities for future research include comparative studies to parse out the effects of different types of peer support, routine reporting of the characteristics of peer support programs, assessment of recovery-oriented outcomes, and partnership with community organizations to optimize trial designs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"27 2","pages":"96-107"},"PeriodicalIF":5.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.70006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olanzapine-Induced Black Hairy Tongue: A Case Report","authors":"Muhammed Fatih Tabara,&nbsp;Beyza Vatan,&nbsp;Mehmet Gurkan Gurok,&nbsp;Murad Atmaca","doi":"10.1111/bdi.70015","DOIUrl":"10.1111/bdi.70015","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"27 4","pages":"329-330"},"PeriodicalIF":5.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting the Training and Educational Priorities of Bipolar Disorder-Focused Early and Mid-Career Researchers and Clinicians","authors":"Norma Verdolini,&nbsp;Rebekah S. Huber,&nbsp;Emma Morton,&nbsp;Tamsyn Van Rheenen,&nbsp;Gabriel Fries,&nbsp;Olivia Dean,&nbsp;Fabiano Gomes,&nbsp;Rachel Mitchell,&nbsp;Georgina M. Hosang,&nbsp;Katie M. Douglas","doi":"10.1111/bdi.70008","DOIUrl":"10.1111/bdi.70008","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"27 3","pages":"246-248"},"PeriodicalIF":5.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research on Youth With and at Risk for Bipolar Disorder: A 5-Year Update","authors":"Mikaela K. Dimick,&nbsp;Xinyue Jiang,&nbsp;Katrin Kutlucinar,&nbsp;Kathryn Burrows,&nbsp;Benjamin I. Goldstein","doi":"10.1111/bdi.70003","DOIUrl":"10.1111/bdi.70003","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"27 3","pages":"176-179"},"PeriodicalIF":5.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Acting Injectables: A Strategy to Mitigate Nonadherence in Bipolar Disorder","authors":"Justin Faden,&nbsp;Elina Maymind","doi":"10.1111/bdi.70005","DOIUrl":"10.1111/bdi.70005","url":null,"abstract":"<p>Despite our best efforts, partial or nonadherence to treatment is common in bipolar disorder. Varying definitions of nonadherence make a clear prevalence difficult to determine, but a recent nationwide bipolar disorder cohort study identified rates of nonadherence to treatment to be as high as 60%, with a mean prevalence of 40% [<span>1</span>]. The study included &gt; 33,000 individuals with bipolar disorder, and approximately 60% were nonadherent at least once during the monitoring period. This begs the question, why? Nonadherence to pharmacologic treatment is not unique to bipolar disorder, but rates are notoriously high in mental health conditions. Reasons are multifactorial but include the number of comorbidities, young age, co-occurring substance use disorders, limited primary support system, psychotic symptoms, intensity of manic symptoms, and limited insight, amongst others [<span>1, 2</span>].</p><p>The consequence of nonadherence to treatment, especially in early disease bipolar disorder, can be dire. Manic exacerbations have been shown to result in brain damage, functional and cognitive impairment, and worse outcomes [<span>3, 4</span>]. Additionally, potentially due to increased impulsivity, bipolar disorder is strongly associated with increased loss of life due to suicide. The best way to prevent these exacerbations and deleterious outcomes is by maintaining adherence to efficacious treatment, thereby preserving brain function and quality of life.</p><p>In a recent article published in bipolar disorders, Vieta and colleagues expound on the landscape of long-acting injectable (LAI) antipsychotics for the treatment of bipolar disorder and provide expert consensus recommendations [<span>4</span>]. Key findings include moving past the preconceived notion that LAIs can be used only for bipolar disorder patients with severe disease, and utilizing LAIs as early as possible in the bipolar disease course, ideally during the first manic episode [<span>4</span>]. Historically, LAIs have been reserved for patients with chronic nonadherence to treatment and schizophrenia. However, robust evidence supports that LAIs can enhance fidelity to treatment, reduce psychotic and manic exacerbations, and reduce the risk of rehospitalization when compared to oral antipsychotics [<span>4</span>].</p><p>Bipolar 1 disorder can be difficult to treat, and individuals will often require multiple medications. However, polypharmacy has also been shown to reduce adherence [<span>1</span>]. LAIs can lower this burden by limiting the number of daily medications, providing consistent medication serum levels, and eliminating the guesswork about treatment adherence status. Using an LAI as the core treatment allows for rational polypharmacy and the utilization of other medications, such as lithium, in a synergistic manner. However, individuals are often not given the option of an LAI due to lack of healthcare provider awareness.</p><p>In recent years, there has been a ","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"27 2","pages":"152-153"},"PeriodicalIF":5.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.70005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacotherapy in Comorbid Bipolar Disorder and Post-Traumatic Stress Disorder From the STEP-BD Cohort","authors":"Samantha E. Russell,&nbsp;Anna L. Wrobel,&nbsp;David R. Skvarc,&nbsp;Mojtaba Lotfaliany,&nbsp;Olivia M. Dean,&nbsp;Melanie M. Ashton,&nbsp;Pedro V. S. Magalhães,&nbsp;Andrew Nierenberg,&nbsp;Michael Berk,&nbsp;Alyna Turner","doi":"10.1111/bdi.70002","DOIUrl":"10.1111/bdi.70002","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Post-traumatic stress disorder (PTSD) is more prevalent in those with bipolar disorder (BD) than in the general population, with rates of PTSD as high as 55% in some BD cohorts. Despite this, little research explores the effects of pharmacotherapy treatments in those with comorbid BD and PTSD. This study aims to explore patterns of pharmacotherapy use at baseline and their impact on symptoms in individuals with BD alone and comorbid BD and PTSD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Systematic Treatment Enhancement Program for BD (STEP-BD) cohort was utilised to examine and compare BD symptoms and pharmacotherapy treatments between those with BD alone (<i>n</i> = 3393) and those with comorbid BD and PTSD (<i>n</i> = 304). We conducted regression models to compare those with and without comorbid PTSD. Models included measures of depression, mania, functioning and quality of life over 24 months of the STEP-BD study. We included baseline pharmacotherapies (lithium, valproate, antidepressants, antipsychotics and benzodiazepines) as predictor outcome variables in all models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At baseline, reported use of lithium was lower in the comorbid BD and PTSD group, while the use of antidepressants, antipsychotics and benzodiazepines was significantly higher in the comorbid BD and PTSD than in the BD alone group. Benzodiazepine use was associated with a small improvement in depression symptom scores and poorer quality of life in those with comorbid BD and PTSD. Lastly, those with comorbid PTSD experienced higher levels of mania and depression symptoms and lower functioning and quality of life compared to BD alone, irrespective of pharmacotherapy treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Clinical trial participants with BD and PTSD reported worse symptoms and outcomes across 24 months of the STEP-BD study compared to those without comorbid PTSD, regardless of baseline medication use. These results highlight the importance of considering comorbidity in the treatment of mental health conditions, specifically BD, and the need for further exploration of effective treatment options.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"27 2","pages":"108-118"},"PeriodicalIF":5.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bdi.70002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Workshopping Depression to Effect Better Recognition","authors":"Gracie Meng-Cin Tsai,&nbsp;Ching-Wen Hung,&nbsp;Erica Bell,&nbsp;Gin Malhi,&nbsp;Chia-Yi Wu","doi":"10.1111/bdi.70004","DOIUrl":"10.1111/bdi.70004","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"27 4","pages":"325-328"},"PeriodicalIF":5.0,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moody Mood Moving Move","authors":"Zhaohui Su","doi":"10.1111/bdi.70001","DOIUrl":"10.1111/bdi.70001","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"27 2","pages":"156"},"PeriodicalIF":5.0,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Major Depression: A Need to Expand Behavioral Activation Research","authors":"Pedro Henrique Nunes Souto,&nbsp;Jainan Rodrigues Barretto,&nbsp;Ricardo Alberto Moreno,&nbsp;Adriana Munhoz Carneiro","doi":"10.1111/bdi.70000","DOIUrl":"10.1111/bdi.70000","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":"27 2","pages":"154-155"},"PeriodicalIF":5.0,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}